# EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)

> **NCT02724644** · PHASE2 · COMPLETED · sponsor: **Endo Pharmaceuticals** · enrollment: 375 (actual)

## Conditions studied

- Edematous Fibrosclerotic Panniculopathy
- Cellulite

## Interventions

- **BIOLOGICAL:** COLLAGENASE CLOSTRIDIUM HISTOLYTICUM
- **BIOLOGICAL:** Placebo Comparator

## Key facts

- **NCT ID:** NCT02724644
- **Lead sponsor:** Endo Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 375 (ACTUAL)
- **Last updated:** 2017-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02724644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02724644, "EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02724644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*